Drug Search Results
More Filters [+]

Davalintide

Alternative Names: davalintide, ac-2307, ac2307, ac 2307
Latest Update: 2023-02-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Amylin Mimetic

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Davalintide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Obesity|Overweight

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CFA104

P2

Completed

Obesity|Overweight

2009-09-01

Recent News Events